The presence of several genes recurrently mutated in myeloid malignancies, such as U2AF1 [125], IDH2R140Q, IDH1R132H, FLT3D835Y, and DNMT3AR882H [126], results in immunogenic neoantigens that appear targetable by clonal T-cell receptor (TCR)-based cellular therapies. This evidence concerns the gene U2AF1 and myeloid neoplasm.